Skip to main content

Researchers Identified the Genetic Causes of Inherited Hearing Loss in the Jewish Population of Israel

Written on |

A New Gene for Human Deafness Found in a Family in Israel

In the Jewish population of Israel, until now, seven genes were known to be involved in hearing loss. Now, thanks to a new study led by Zippora Brownstein, PhD, and Prof. Karen Avraham from the Sackler Faculty of Medicine at Tel Aviv University, the number of genes known to be responsible for inherited hearing loss in Israeli Jewish families is 32.

These results have immediate implications for genetic counseling for families with hearing loss and for care of children with hearing loss. The research was in cooperation with scientists from multiple Israeli universities and hospitals, and from the University of Washington in Seattle, the U.S. National Institutes of Health (NIH), Bethlehem University, the University of Iceland, and the University of Maryland. The researchers also identified a mutation in a gene not previously recognized to cause hearing loss in humans. This breakthrough research was published recently in the journal Clinical Genetics.

The 25th gene

More than 150 genes are known to science to be involved in hearing loss. Genetic diagnoses for inherited hearing loss have previously been difficult, both world wide and in Jewish communities, because any one of so many different genes, and any of many mutations in each gene, could be the cause. Until now, mutations in only seven of the 150 genes had been detected among persons with hearing loss in the Jewish population of Israel. In the current study, which included 88 Israeli families with hearing loss, the researchers identified mutations in 25 additional genes.

Although 24 of the 25 genes are known to cause hearing loss in families worldwide, most of the specific mutations in Israeli Jewish families are newly observed and thus far known only the Jewish community. The 25th gene, called ATOH1, was found for the first time to cause hearing loss in humans.

Organ of Corti of the inner ear labelled with antibodies to show sensory hair cells responsible for hearing. Photo Credit: Shahar Taiber & Prof. Karen Avraham

“We know that ATOH1 has an important role in the ear,” explains Prof. Avraham, “without it, hair cells of the inner ear – the cells responsible for our hearing – cannot develop properly. Until now, a mutation in this gene was identified only in mice, and the mice had a hearing loss. We found a similar mutation in relatives with hearing loss in a large family in Israel – the first people in the world known to have a mutation in this gene. I believe we will find more families, both in Israel and abroad, with mutations in this gene that cause hearing loss. The goal is that with this information, new treatment possibilities for people with hearing loss will be developed – including gene therapy.”

Prof. Avraham adds: “We surveyed Jewish families throughout Israel with all types of hearing loss: from congenital to older age at onset, and from moderate to profound. Our survey exploited advanced gene sequencing technology, including a custom gene panel that we created, called HEar-Seq. This custom gene panel allowed us to simultaneously sequence all 150 genes known to be involved in hearing loss, and many “candidate genes” as well. HEar-Seq revealed the distribution of genes and their mutations responsible for hearing loss in all the Jewish communities that make up modern Israel. It led us to ATOH1.

Our discoveries have immediate implications for genetic counseling, which can enable families to prevent additional cases of hearing loss through pre-gestational genetic diagnosis and in-vitro fertilization. Also, for many families, treatment and rehabilitation for hearing loss can be tailored to the family’s specific mutation. The findings of this study allow doctors and audiologists in Israel to provide personally tailored treatment to patients with inherited hearing loss.”

The study was funded by the National Institute of Deafness and Communication Disorders of the U.S. National Institutes of Health, the Israel Precision Medicine Program of the Israel Science Foundation, the Ernest and Bonnie Beutler Research Program of Excellence in Genomic Medicine, the Hedrich Charitable Trust, and travel grants from the University of Washington Virginia Bloedel Hearing Research Institute.

Prof. Karen Avraham

Zippora Brownstein, PhD

Related posts

GPS for Cancer: Directing Drugs to the Tumor

23 December 2024

Is Treatment for Genetic Autism on the Horizon?

25 November 2024

Nasal Spray Revolutionizes COVID Protection

21 November 2024

Is There a Way to Stop Parkinson’s Disease at Its Source?

14 November 2024

How Does the Brain Keep Calm?

14 November 2024

Hyperbaric Oxygen Therapy: A Promising Treatment for PTSD Symptoms

11 November 2024

TAU Breakthrough Reveals Mechanism That Eliminates Tumors

3 November 2024

Could Cancer Vulnerabilities Be Hidden in Chromosome Changes?

23 September 2024

Spotting Parkinson’s Early: A New TAU Breakthrough

17 September 2024

How Can We See Through Closed Eyes?

16 September 2024

Can Parkinson’s Treatment be Enhanced by AI Tech?

1 September 2024

Want to Fall in Love? Step Outside in The Sun

19 August 2024

Can Smartwatches Prevent Pandemic Outbreaks?

7 August 2024

How Close Are We to Thought-Based Communication?

22 July 2024

Will Wearable Tech Transform Neurological Diagnosis?

21 July 2024

Will Existing Drugs Stop Cancer’s Bone Spread?

19 May 2024

Victoria

Tok Corporate Centre, Level 1,
459 Toorak Road, Toorak VIC 3142
Phone: +61 3 9296 2065
Email: [email protected]

New South Wales

Level 22, Westfield Tower 2, 101 Grafton Street, Bondi Junction NSW 2022
Phone: +61 418 465 556
Email: [email protected]

Western Australia

P O Box 36, Claremont,
WA  6010
Phone: :+61 411 223 550
Email: [email protected]